Empagliflozin in Heart Failure Dialysis Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.
Epistemonikos ID: 868c859b9ab1c7c8f468beca7a82f0753eb5a101
First added on: May 15, 2024